Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation

Medicine & Life Sciences

• 4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidine-4-carboxamide 100%
• IGF Type 1 Receptor 64%
• Insulin Receptor 57%
• Estrogens 41%
• Breast Neoplasms 32%
• Somatomedins 32%
• AZD9362 26%
• Heterografts 22%
• Fulvestrant 20%
• Receptor Protein-Tyrosine Kinases 16%
• Up-Regulation 14%
• Hormones 14%
• Phosphatidylinositol 3-Kinase 10%
• Insulin-Like Growth Factor I 10%
• AZD4547 9%
• Growth 7%
• Ligands 7%
• Phosphorylation 6%
• Western Blotting 6%
• Fibroblast Growth Factor Receptors 6%
• Estrogen Receptor Modulators 6%
• Insulin-Like Growth Factor Binding Protein 3 6%
• Insulin-Like Growth Factor II 6%
• Membranes 6%
• Therapeutics 5%
• MCF-7 Cells 5%
• Tamoxifen 5%
• Nude Mice 4%
• Estrogen Receptors 4%
• Fluorescent Antibody Technique 4%
• Adenosine Triphosphate 3%
• Enzyme-Linked Immunosorbent Assay 3%
• Cell Line 3%
• Messenger RNA 2%
• Pharmaceutical Preparations 2%
• Neoplasms 1%